Share Price and Basic Stock Data
Last Updated: November 9, 2024, 11:47 pm
PEG Ratio | 0.00 |
---|
Competitors of Solara Active Pharma Sciences Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd | 3,565 Cr. | 327 | 390/108 | 67.6 | 20.5 | 0.20 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 61.1 Cr. | 82.3 | 94.9/22.7 | 23.4 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 25.8 Cr. | 17.6 | 19.5/7.60 | 33.6 | 6.64 | 0.00 % | 4.06 % | 3.33 % | 10.0 |
Godavari Drugs Ltd | 91.3 Cr. | 121 | 155/87.0 | 14.2 | 51.8 | 0.00 % | 12.7 % | 15.5 % | 10.0 |
Glenmark Life Sciences Ltd | 13,431 Cr. | 1,096 | 1,335/620 | 31.7 | 207 | 2.05 % | 28.1 % | 21.1 % | 2.00 |
Industry Average | 20,217.39 Cr | 1,275.35 | 61.75 | 190.31 | 0.31% | 16.78% | 15.93% | 6.64 |
Quarterly Result
Month | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 444 | 406 | 402 | 100 | 361 | 330 | 338 | 395 | 381 | 352 | 425 | 249 | 299 |
Expenses | 345 | 314 | 330 | 197 | 347 | 318 | 311 | 350 | 332 | 333 | 388 | 410 | 290 |
Operating Profit | 99 | 91 | 72 | -97 | 14 | 13 | 28 | 45 | 49 | 19 | 38 | -162 | 10 |
OPM % | 22% | 23% | 18% | -97% | 4% | 4% | 8% | 11% | 13% | 5% | 9% | -65% | 3% |
Other Income | 10 | 5 | 3 | 3 | 5 | 7 | 4 | 7 | 5 | 2 | -4 | -62 | -120 |
Interest | 25 | 19 | 17 | 18 | 21 | 22 | 22 | 24 | 22 | 25 | 24 | 25 | 31 |
Depreciation | 27 | 28 | 28 | 28 | 28 | 28 | 29 | 28 | 26 | 26 | 26 | 26 | 25 |
Profit before tax | 57 | 50 | 30 | -140 | -31 | -31 | -19 | 1 | 5 | -29 | -17 | -275 | -167 |
Tax % | 0% | -0% | -0% | -0% | 106% | 47% | 48% | 22% | 25% | 35% | -0% | -0% | -53% |
Net Profit | 57 | 50 | 30 | -140 | 2 | -16 | -10 | 0 | 4 | -19 | -17 | -275 | -255 |
EPS in Rs | 11.83 | 10.47 | 6.20 | -29.20 | 0.39 | -3.42 | -2.08 | 0.09 | 0.79 | -4.07 | -3.58 | -57.36 | -53.20 |
Last Updated: Unknown
Profit & Loss - Annual Report
Last Updated: Unknown
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|
Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,337 |
Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,409 |
Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | -72 |
OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | -5% |
Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | -186 |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 111 |
Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 102 |
Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | -473 |
Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | |
Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | -561 |
EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | -117.88 | |
Dividend Payout % | 0% | 22% | 5% | 11% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|
YoY Net Profit Growth (%) | 94.92% | 92.17% | -126.24% | 62.07% | -2477.27% |
Change in YoY Net Profit Growth (%) | 0.00% | -2.74% | -218.42% | 188.31% | -2539.34% |
Solara Active Pharma Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | -7% |
TTM: | -19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -1456% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | -11% |
1 Year: | 164% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -11% |
Last Year: | -34% |
Last Updated: Unknown
Balance Sheet
Last Updated: Unknown
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 |
Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 |
Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 |
Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 |
Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 |
Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 |
CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 |
Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 |
Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 |
Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 |
Cash Flow
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Free Cash Flow | -576.00 | -325.00 | -462.00 | -235.00 | 80.00 | 133.00 | -96.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 |
Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 |
Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 |
Working Capital Days | 107 | 34 | 67 | 118 | 251 | 213 | 126 |
ROCE % | 10% | 12% | 15% | -0% | 2% | -9% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Aditya Birla Sun Life Flexi Cap Fund | 420,000 | 0.08 | 15.17 | 420,000 | 2024-10-27 | 0% |
Aditya Birla Sun Life Midcap Fund | 130,000 | 0.09 | 4.7 | 420,000 | 2024-10-27 | -69.05% |
Aditya Birla Sun Life Manufacturing Equity Fund | 65,000 | 0.29 | 2.35 | 420,000 | 2024-10-27 | -84.52% |
Motilal Oswal S&P BSE Healthcare ETF | 183 | 0.07 | 0.01 | 420,000 | 2024-10-27 | -99.96% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | -157.62 | -6.16 | -16.18 | 69.00 | 44.29 |
Diluted EPS (Rs.) | -157.62 | -6.16 | -16.18 | 64.53 | 42.82 |
Cash EPS (Rs.) | -128.79 | 24.70 | 15.01 | 91.87 | 77.72 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 260.16 | 417.35 | 424.22 | 443.42 | 370.29 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 260.16 | 417.35 | 424.22 | 443.42 | 370.29 |
Revenue From Operations / Share (Rs.) | 358.03 | 401.06 | 352.32 | 450.13 | 492.27 |
PBDIT / Share (Rs.) | -24.95 | 43.45 | 27.77 | 115.43 | 106.88 |
PBIT / Share (Rs.) | -53.65 | 12.57 | -3.42 | 85.18 | 71.81 |
PBT / Share (Rs.) | -135.67 | -12.45 | -25.31 | 61.66 | 42.80 |
Net Profit / Share (Rs.) | -157.49 | -6.18 | -16.19 | 61.62 | 42.65 |
NP After MI And SOA / Share (Rs.) | -157.61 | -6.16 | -16.15 | 61.64 | 42.69 |
PBDIT Margin (%) | -6.96 | 10.83 | 7.88 | 25.64 | 21.71 |
PBIT Margin (%) | -14.98 | 3.13 | -0.97 | 18.92 | 14.58 |
PBT Margin (%) | -37.89 | -3.10 | -7.18 | 13.69 | 8.69 |
Net Profit Margin (%) | -43.98 | -1.54 | -4.59 | 13.68 | 8.66 |
NP After MI And SOA Margin (%) | -44.02 | -1.53 | -4.58 | 13.69 | 8.67 |
Return on Networth / Equity (%) | -60.76 | -1.47 | -3.81 | 13.93 | 11.57 |
Return on Capital Employeed (%) | -17.42 | 2.51 | -0.65 | 16.76 | 13.54 |
Return On Assets (%) | -24.13 | -0.76 | -1.96 | 8.47 | 5.32 |
Long Term Debt / Equity (X) | 0.11 | 0.15 | 0.18 | 0.09 | 0.23 |
Total Debt / Equity (X) | 1.07 | 0.66 | 0.67 | 0.32 | 0.59 |
Asset Turnover Ratio (%) | 0.49 | 0.49 | 0.45 | 0.67 | 0.64 |
Current Ratio (X) | 0.64 | 1.08 | 1.16 | 1.34 | 0.92 |
Quick Ratio (X) | 0.35 | 0.57 | 0.61 | 0.96 | 0.53 |
Inventory Turnover Ratio (X) | 1.66 | 1.37 | 1.97 | 2.38 | 2.49 |
Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | -18.53 | 8.90 | 13.63 |
Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 19.90 | 5.97 | 7.48 |
Earning Retention Ratio (%) | 0.00 | 0.00 | 118.53 | 91.10 | 86.37 |
Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 80.10 | 94.03 | 92.52 |
Interest Coverage Ratio (X) | -0.85 | 1.74 | 1.33 | 4.91 | 3.68 |
Interest Coverage Ratio (Post Tax) (X) | -2.58 | 0.75 | 0.27 | 3.62 | 2.47 |
Enterprise Value (Cr.) | 2334.97 | 2176.74 | 3374.17 | 5329.56 | 1723.87 |
EV / Net Operating Revenue (X) | 1.81 | 1.51 | 2.66 | 3.30 | 1.30 |
EV / EBITDA (X) | -26.00 | 13.92 | 33.74 | 12.85 | 6.01 |
MarketCap / Net Operating Revenue (X) | 1.04 | 0.81 | 1.89 | 3.10 | 0.90 |
Retention Ratios (%) | 0.00 | 0.00 | 118.53 | 91.09 | 86.36 |
Price / BV (X) | 1.44 | 0.78 | 1.57 | 3.15 | 1.20 |
Price / Net Operating Revenue (X) | 1.04 | 0.81 | 1.89 | 3.10 | 0.90 |
EarningsYield | -0.42 | -0.01 | -0.02 | 0.04 | 0.09 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Solara Active Pharma Sciences Ltd:
- Net Profit Margin: -43.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -17.42% (Industry Average ROCE: 16.78%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -60.76% (Industry Average ROE: 15.93%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.35
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 61.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.07
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -43.98%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | 201, Devavrata, Sector 17, Vashi, New Mumbai Maharashtra 400703 | investors@solara.co.in http://www.solara.co.in |
Management | |
---|---|
Name | Position Held |
Mr. R Ramakrishnan | Chairman & Ind.Director |
Mr. Poorvank Purohit | Managing Director & CEO |
Mr. Mohan Muthunarayanan | COO & Executive Director |
Mr. Manish Gupta | Non Executive Director |
Mr. Kartheek Chintalapati Raju | Non Executive Director |
Mr. Arun Kumar | Non Executive Director |
Dr. Kausalya Santhanam | Independent Director |
Mr. Rajiv Vijay Nabar | Independent Director |
Mr. Rajendra Kumar Srivastava | Independent Director |
FAQ
What is the latest fair value of Solara Active Pharma Sciences Ltd?
The latest fair value of Solara Active Pharma Sciences Ltd is ₹1547.90.
What is the Market Cap of Solara Active Pharma Sciences Ltd?
The Market Cap of Solara Active Pharma Sciences Ltd is 3,473 Cr..
What is the current Stock Price of Solara Active Pharma Sciences Ltd as on 10 November 2024?
The current stock price of Solara Active Pharma Sciences Ltd as on 10 November 2024 is 798.
What is the High / Low of Solara Active Pharma Sciences Ltd stocks in FY 2024?
In FY 2024, the High / Low of Solara Active Pharma Sciences Ltd stocks is 851/292.
What is the Stock P/E of Solara Active Pharma Sciences Ltd?
The Stock P/E of Solara Active Pharma Sciences Ltd is .
What is the Book Value of Solara Active Pharma Sciences Ltd?
The Book Value of Solara Active Pharma Sciences Ltd is 302.
What is the Dividend Yield of Solara Active Pharma Sciences Ltd?
The Dividend Yield of Solara Active Pharma Sciences Ltd is 0.00 %.
What is the ROCE of Solara Active Pharma Sciences Ltd?
The ROCE of Solara Active Pharma Sciences Ltd is 8.67 %.
What is the ROE of Solara Active Pharma Sciences Ltd?
The ROE of Solara Active Pharma Sciences Ltd is 33.5 %.
What is the Face Value of Solara Active Pharma Sciences Ltd?
The Face Value of Solara Active Pharma Sciences Ltd is 10.0.